The Campaign for Fair Pharmaceutical Competition has launched a statewide campaign to urge Sen. Orrin Hatch, R-Utah, to reform the Hatch-Waxman Act.

The act allows brand-name drug companies to overcharge consumers for drugs, according to the campaign. The campaign wants consumers to ask Congress to change loopholes in the act to eliminate what it calls anti-competitive practices by the brand industry.It also hopes to build a coalition among the state's senior, consumer and women's groups to push the reforms.